Navigation Links
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Date:11/16/2007

WILMINGTON, Del., Nov. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for maintenance treatment of schizophrenia in adult patients. On May 17, 2007, the FDA approved SEROQUEL XR for the acute treatment of schizophrenia in adult patients.

Schizophrenia patients experience high rates of symptom relapse, and as a result, there is an important need for long-term treatment options for schizophrenia to help reduce the risk of the recurrence of acute psychotic episodes. (1,2)

In the clinical trial supporting this approval, patients with schizophrenia who were treated with SEROQUEL XR experienced a significantly longer time to relapse, compared with patients receiving placebo. Patients receiving SEROQUEL XR demonstrated an 84% reduction in the relative risk of relapse (hazard ratio 0.16; p<0.0001). Results showed the estimated risk of relapse after six months was 14.3% in the SEROQUEL XR group versus 68.2% in the placebo group (p<0.0001). Differences in relapse rate between active treatment and placebo were large enough to require the study to be stopped early. The complete results of the clinical trial appear in the November issue of the journal Psychiatry 2007.(3)

"Today's FDA approval helps address the need for longer-term treatment options for patients with schizophrenia," said Mark Scott, Ph.D., Executive Director for Development, AstraZeneca. "The clinical trial results provided compelling evidence for reducing the risk of relapse when these patients are treated with SEROQUEL XR."

Schizophrenia is a serious brain disorder with symptoms including distorted perceptions of reality, hallucinations and delusions, illogical thinking, and flat or blunted emotions, affecting over 2 million American adults -- about 1% of the population 18 years and older.(4,5)

The FDA approval for main
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BERGEN, Norway , September 23, 2014 /PRNewswire/ ... "Company"), an oncology biopharmaceutical company, today announces it ... million) Seeding Drug Discovery Award from the UK,s ... against BGB002, its proprietary, novel cancer target. ... are to identify and fund especially promising, innovative ...
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... additions to its Scientific Advisory Board.  The new members ... Davies , PhD. Dr. Acker is a ...
Breaking Medicine Technology:BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... Harco Metal Products (Harco), an industry leader in tube fabrication, systems ... manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products for health ... cost associated with staff injuries caused by physically lifting and moving ...
... 23 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... 26, 2010 , at 8:00 a.m. Eastern Time ( 5:00 ... , , ... live webcast of the presentation on the company,s website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar ...
Cached Medicine Technology:Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib 2
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Wellesley, Mass., September 23, 2014 – BCC Research ( ... Joint Reconstruction and Replacement: Materials, Technologies, and Global Markets ... is expected to increase to nearly $16.2 billion by ... 4.2% from 2013 through 2018. The U.S. occupies the ... CAGR of 5.1%. , Revision and partial joint replacement ...
(Date:9/23/2014)... eCaring, a leading health care quality ... contract to provide its unique Web-based home health care ... New York City’s largest not-for-profit health plans. Elderplan, an ... to help enhance the care of its Medicare, Medicaid ... Elderplan has been at the forefront of offering New ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... revenue for the Fruit and Vegetable Markets ... consumption and fruit prices benefited operators over the ... industry follow unique preference and demographic trends, including ... US population. While per capita fruit and vegetable ...
(Date:9/23/2014)... the results of their cancer research at ESMO ... Joint Symposium: ESMO-ASCO: The Evolution of the ... AM - 12:30 PM, Room: Granada, Abstract 121IN: ... new forms of cancer clinical research? The example ... Paper session: Melanoma and other skin tumors , ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3
... new study has established the wholesomeness of whole wheat ... breast cancer risk in the offspring.// ,Dr ... her colleagues examined the benefits of dietary changes on ... health. These results could well mimic the occurrence in ...
... health care for patients that was released by the ... countries, except the U.S. ,In the survey ... was found that Canada lagged in several aspects including ... doctors availability after hours, multi-discipline teams for treatment of ...
... to arouse strong feelings either way has been brought up ... the proposal suggests mercy killing of// new borns who are ... Gynaecology put forth this recommendation as the solution to the ... are being kept alive because of the advanced technology ...
... 7 and the theme selected is Cancer and Women. ... on that day// to promote awareness and motivate people ... ,"Run 4 Cancer" will be flagged off by SSP ... Allahabad Division RN Tripathi will preside over a lecture ...
... a biotechnology firm based in Seattle has called off further ... year following the untimely deaths// of few of the patients ... efficacy of the cancer drug Xyotax. ,The CEO of ... the volunteer s who were cancer patients do not seem ...
... raising the retirement age for civil servants from 60 to ... soaring pension bill//. ,Moreover, improving health standards and ... retiring are being cited among the reasons for the move. ... Reforms (NCGR) told The News International that the reform body ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Awareness about Women's Cancers- A National Concern 2Health News:Multiple deaths forces cancer trial to be called off 2Health News:Pakistan civil servants may retire at 62 2
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
... Featuring new technology, such as a recessed ... and lens housings, this arthroscope has superior ... by EO, Steris and steam autoclaving or ... Light post/adapters to fit ACMI, Wolf, Dyonics ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
Medicine Products: